Episode Details

A groundbreaking new drug, amivantamab, is rewriting the playbook for advanced head and neck cancer—offering hope where none existed before. In trial OrigAMI-4, over 100 patients who’d failed standard treatments saw tumors shrink or vanish, with 15 achieving complete remission. This triple-action drug targets cancer’s fuel, dodges its defenses, and rallies the immune system—all via a simple injection. Real-life impact? One patient, Carl Walsh, went from struggling with tongue cancer to savoring steak again. For HPV-negative cancers, notoriously tough to treat, the median survival jumped to 12.5 months. Experts call it a major leap forward—a beacon of hope for patients with few options left.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/78d834c063847da9